IPF lung disease numbers are rising quickly to become a significant cause of mortality in UK

April 28, 2011, British Medical Journal

The number of cases of idiopathic pulmonary fibrosis (IPF) has continued to rise significantly in the first decade of the 21st century and could lead to more deaths than ovarian cancer, lymphoma, leukaemia, or kidney cancer, reveals research published ahead of print in the Thorax journal.

IPF is the most common of the pneumonias that happen without an apparent cause and previous studies have shown that incidence and deaths from the disease are rising in the UK and the USA.

However, there is currently no mandatory registration of IPF diagnoses in the UK or anywhere else in the world.

Researchers from the Nottingham Respiratory Biomedical Research Unit and the University of Nottingham set out to determine the trends in incidence of this disease.

The researchers used two different sets of data to investigate whether the incidence of pulmonary fibrosis in the 21st century was still growing in the UK.

These data were routine from the Office for National Statistics (ONS) between 1968 and 2008 and The Health Improvement Network (THIN), a computerised longitudinal primary care database recorded by UK GPs in 446 general practices.

Using the definition of idiopathic clinical syndrome (IPF-CS), they found that there were 56,675 deaths attributed to IPF-CS in England and Wales from 1968 to 2008. The number of recorded deaths increased from 479 in 1968 to 3,019 in 2008.

Annual death certificate recordings of the disease rose six-fold across the study period from 0.92 per 100,000 people in the 1968-1972 period, to 5.1 per 100,000 people in the 2006-2008 period.

Numbers of cases recorded in primary care rose by 35% from 2000 to 2008 with an overall incidence rate of 7.44 per 100,000 person years. Incidence was highest in men, the older population and in north-west England.

Using these figures, the researchers estimate that there are currently around 15,000 people in the UK with a diagnosis of the disease, and that 5,000 new cases will be diagnosed each year, with around 5,000 people with the disease dying.

This would mean more people in the UK dying each year from IPF-CS than from , lymphoma, , mesothelioma or .

The authors conclude: " At the moment, we do not understand what causes IPF-CS, why the incidence is on the rise or how best to treat individuals with this disease spectrum.

"It is clear that IPF-CS is an important public health problem and warrants more research investment."

Related Stories

Recommended for you

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Flu shot only 36 percent effective, making bad year worse (Update)

February 15, 2018
The flu vaccine is doing a poor job protecting older Americans and others against the bug that's causing most illnesses.

IFN-mediated immunity to influenza A virus infection influenced by RIPK3 protein

February 15, 2018
Each year, influenza kills half a million people globally with the elderly and very young most often the victims. In fact, the Centers for Disease Control and Prevention reported 37 children have died in the United States ...

A new class of drug to treat herpes simplex virus-1 infection

February 14, 2018
For patients with the herpes simplex-1 virus (HSV-1), there are just a handful of drugs available to treat the painful condition that can affect the eyes, mouth and genitals.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.